Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Anti-Bacterial Agents | 26 | 2020 | 402 | 3.620 |
Why?
|
Daptomycin | 9 | 2013 | 13 | 1.780 |
Why?
|
Staphylococcal Infections | 6 | 2018 | 176 | 1.370 |
Why?
|
Prosthesis-Related Infections | 7 | 2020 | 214 | 1.220 |
Why?
|
Anti-Infective Agents | 11 | 2005 | 63 | 1.100 |
Why?
|
Cross Infection | 5 | 2023 | 298 | 1.100 |
Why?
|
Bacterial Infections | 6 | 2011 | 69 | 0.970 |
Why?
|
Gram-Positive Bacterial Infections | 5 | 2013 | 57 | 0.960 |
Why?
|
Fluoroquinolones | 8 | 2011 | 26 | 0.940 |
Why?
|
Clostridium Infections | 1 | 2023 | 18 | 0.930 |
Why?
|
Communicable Diseases | 1 | 2023 | 24 | 0.930 |
Why?
|
Staphylococcus aureus | 7 | 2018 | 85 | 0.840 |
Why?
|
Infection Control | 3 | 2018 | 169 | 0.800 |
Why?
|
Catheterization, Central Venous | 2 | 2011 | 39 | 0.710 |
Why?
|
Skin Diseases, Bacterial | 3 | 2018 | 5 | 0.670 |
Why?
|
Surgical Wound Infection | 2 | 2017 | 97 | 0.660 |
Why?
|
Sepsis | 3 | 2011 | 144 | 0.660 |
Why?
|
Bacteria | 4 | 2011 | 77 | 0.650 |
Why?
|
Soft Tissue Infections | 3 | 2018 | 28 | 0.640 |
Why?
|
Bacteremia | 2 | 2010 | 115 | 0.610 |
Why?
|
Enterococcus | 4 | 2013 | 56 | 0.590 |
Why?
|
Humans | 54 | 2023 | 29337 | 0.580 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 124 | 0.560 |
Why?
|
Arthroplasty, Replacement | 1 | 2017 | 147 | 0.530 |
Why?
|
Microbial Sensitivity Tests | 13 | 2018 | 111 | 0.490 |
Why?
|
Endocarditis, Bacterial | 2 | 2006 | 10 | 0.470 |
Why?
|
Oxazolidinones | 2 | 2010 | 6 | 0.460 |
Why?
|
Acetamides | 2 | 2010 | 7 | 0.450 |
Why?
|
Vancomycin Resistance | 2 | 2010 | 28 | 0.450 |
Why?
|
Drug Resistance, Bacterial | 3 | 2011 | 53 | 0.430 |
Why?
|
Chlamydia trachomatis | 5 | 1994 | 18 | 0.420 |
Why?
|
Quinolones | 5 | 1991 | 21 | 0.390 |
Why?
|
Methicillin Resistance | 2 | 2008 | 31 | 0.390 |
Why?
|
Retrospective Studies | 11 | 2023 | 3273 | 0.350 |
Why?
|
Antibiotic Prophylaxis | 3 | 2016 | 36 | 0.350 |
Why?
|
Catheters, Indwelling | 1 | 2008 | 25 | 0.330 |
Why?
|
Diagnostic Tests, Routine | 2 | 2019 | 16 | 0.330 |
Why?
|
Hospitals, University | 1 | 2008 | 39 | 0.320 |
Why?
|
Attitude of Health Personnel | 1 | 2009 | 148 | 0.320 |
Why?
|
Benchmarking | 1 | 2008 | 41 | 0.320 |
Why?
|
Pneumonia, Bacterial | 2 | 2005 | 9 | 0.310 |
Why?
|
Quality of Health Care | 2 | 2011 | 138 | 0.310 |
Why?
|
Diarrhea | 4 | 1999 | 48 | 0.310 |
Why?
|
Cefazolin | 2 | 2018 | 5 | 0.300 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2009 | 194 | 0.300 |
Why?
|
Gram-Negative Bacterial Infections | 2 | 2007 | 24 | 0.290 |
Why?
|
Erythromycin | 2 | 1996 | 11 | 0.270 |
Why?
|
Bone Diseases | 1 | 2005 | 24 | 0.270 |
Why?
|
United States | 6 | 2017 | 2333 | 0.270 |
Why?
|
Gram-Negative Aerobic Bacteria | 1 | 2005 | 5 | 0.270 |
Why?
|
Microbiological Techniques | 2 | 2016 | 9 | 0.270 |
Why?
|
Critical Care | 1 | 2008 | 234 | 0.270 |
Why?
|
Arthroplasty, Replacement, Knee | 3 | 2020 | 696 | 0.260 |
Why?
|
Arthroplasty, Replacement, Hip | 3 | 2020 | 863 | 0.260 |
Why?
|
Ambulatory Care | 1 | 2005 | 75 | 0.260 |
Why?
|
Infection Control Practitioners | 1 | 2004 | 2 | 0.250 |
Why?
|
Joint Diseases | 1 | 2005 | 110 | 0.250 |
Why?
|
Equipment Contamination | 1 | 2004 | 24 | 0.250 |
Why?
|
Ambulatory Care Facilities | 1 | 2004 | 37 | 0.240 |
Why?
|
Carrier State | 2 | 2018 | 53 | 0.230 |
Why?
|
Knee Prosthesis | 2 | 2020 | 248 | 0.230 |
Why?
|
Hospitals | 1 | 2023 | 157 | 0.220 |
Why?
|
Treatment Outcome | 10 | 2015 | 3478 | 0.210 |
Why?
|
Disease Management | 2 | 2019 | 114 | 0.200 |
Why?
|
Hip Prosthesis | 3 | 2020 | 605 | 0.190 |
Why?
|
Cephalosporins | 3 | 1997 | 17 | 0.190 |
Why?
|
Adult | 13 | 2018 | 8601 | 0.190 |
Why?
|
Orthopedic Fixation Devices | 1 | 1999 | 24 | 0.180 |
Why?
|
Heart Valve Prosthesis | 1 | 1999 | 22 | 0.180 |
Why?
|
Male | 17 | 2020 | 15621 | 0.180 |
Why?
|
Discitis | 1 | 2019 | 4 | 0.180 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 31 | 0.180 |
Why?
|
Genes, Bacterial | 1 | 2018 | 6 | 0.170 |
Why?
|
Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 13 | 0.170 |
Why?
|
Linezolid | 2 | 2010 | 6 | 0.160 |
Why?
|
Middle Aged | 12 | 2020 | 9823 | 0.160 |
Why?
|
Enterobacteriaceae Infections | 1 | 2018 | 38 | 0.160 |
Why?
|
Fasciitis, Necrotizing | 1 | 2018 | 4 | 0.160 |
Why?
|
Ciprofloxacin | 4 | 1993 | 29 | 0.160 |
Why?
|
Reoperation | 2 | 2020 | 932 | 0.150 |
Why?
|
Aged | 10 | 2020 | 9448 | 0.150 |
Why?
|
Meningitis, Bacterial | 1 | 1996 | 8 | 0.150 |
Why?
|
Mass Screening | 1 | 2018 | 177 | 0.150 |
Why?
|
Legionella pneumophila | 1 | 1996 | 1 | 0.150 |
Why?
|
Clarithromycin | 1 | 1996 | 5 | 0.150 |
Why?
|
Azithromycin | 1 | 1996 | 4 | 0.140 |
Why?
|
Campylobacter Infections | 3 | 1993 | 12 | 0.140 |
Why?
|
Prosthesis Failure | 1 | 2020 | 556 | 0.140 |
Why?
|
Female | 13 | 2020 | 16197 | 0.140 |
Why?
|
Oxacillin | 1 | 2015 | 2 | 0.140 |
Why?
|
Methicillin | 1 | 2015 | 6 | 0.140 |
Why?
|
Chicago | 4 | 2018 | 865 | 0.140 |
Why?
|
Arthroplasty | 1 | 2016 | 136 | 0.140 |
Why?
|
Drug Hypersensitivity | 1 | 1995 | 17 | 0.130 |
Why?
|
Sexually Transmitted Diseases, Bacterial | 2 | 1991 | 3 | 0.130 |
Why?
|
Aged, 80 and over | 6 | 2018 | 4851 | 0.130 |
Why?
|
Ceftizoxime | 1 | 1994 | 2 | 0.130 |
Why?
|
Neisseria gonorrhoeae | 2 | 1991 | 7 | 0.120 |
Why?
|
Cyclic N-Oxides | 1 | 1993 | 5 | 0.120 |
Why?
|
Campylobacter | 1 | 1993 | 8 | 0.120 |
Why?
|
Endocarditis | 1 | 2013 | 8 | 0.120 |
Why?
|
Quinoxalines | 1 | 1993 | 11 | 0.120 |
Why?
|
Enterococcus faecalis | 1 | 2013 | 7 | 0.120 |
Why?
|
Enterococcus faecium | 1 | 2013 | 15 | 0.120 |
Why?
|
Drug Resistance, Microbial | 4 | 1996 | 96 | 0.110 |
Why?
|
Drainage | 1 | 2013 | 50 | 0.110 |
Why?
|
Campylobacter jejuni | 1 | 1992 | 4 | 0.110 |
Why?
|
Uterine Cervicitis | 1 | 1991 | 2 | 0.110 |
Why?
|
Urethritis | 1 | 1991 | 2 | 0.110 |
Why?
|
Cohort Studies | 3 | 2015 | 1939 | 0.110 |
Why?
|
Aza Compounds | 1 | 2011 | 1 | 0.110 |
Why?
|
Administration, Ophthalmic | 1 | 2011 | 1 | 0.110 |
Why?
|
Azepines | 1 | 2011 | 6 | 0.100 |
Why?
|
Quinolines | 1 | 2011 | 16 | 0.100 |
Why?
|
Risk Factors | 2 | 2011 | 2443 | 0.100 |
Why?
|
4-Quinolones | 4 | 1995 | 6 | 0.100 |
Why?
|
Serratia marcescens | 1 | 2010 | 11 | 0.100 |
Why?
|
Serratia Infections | 1 | 2010 | 10 | 0.100 |
Why?
|
Naphthyridines | 1 | 1990 | 2 | 0.100 |
Why?
|
Risk Reduction Behavior | 1 | 2011 | 55 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2011 | 144 | 0.090 |
Why?
|
Health Care Costs | 1 | 2011 | 70 | 0.090 |
Why?
|
Data Interpretation, Statistical | 1 | 2010 | 96 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2010 | 88 | 0.090 |
Why?
|
Doxycycline | 4 | 2006 | 22 | 0.090 |
Why?
|
Illinois | 1 | 2011 | 241 | 0.090 |
Why?
|
Multivariate Analysis | 1 | 2010 | 324 | 0.090 |
Why?
|
Tetracyclines | 1 | 1989 | 3 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2018 | 301 | 0.090 |
Why?
|
Models, Biological | 1 | 2011 | 343 | 0.090 |
Why?
|
Rifampin | 1 | 1989 | 7 | 0.090 |
Why?
|
Minocycline | 1 | 1989 | 8 | 0.090 |
Why?
|
Shock, Septic | 1 | 1989 | 62 | 0.080 |
Why?
|
Time Factors | 4 | 2020 | 1616 | 0.080 |
Why?
|
Neurocognitive Disorders | 1 | 1988 | 19 | 0.080 |
Why?
|
Algorithms | 1 | 2010 | 400 | 0.080 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 1988 | 90 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2008 | 67 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2008 | 39 | 0.080 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2007 | 16 | 0.080 |
Why?
|
Vancomycin | 1 | 2008 | 57 | 0.080 |
Why?
|
Skin Diseases, Infectious | 1 | 2007 | 9 | 0.080 |
Why?
|
Prognosis | 1 | 2010 | 840 | 0.080 |
Why?
|
Q Fever | 1 | 2006 | 4 | 0.070 |
Why?
|
Travel | 1 | 2006 | 13 | 0.070 |
Why?
|
Community-Acquired Infections | 2 | 2005 | 78 | 0.070 |
Why?
|
Registries | 1 | 2007 | 188 | 0.070 |
Why?
|
Tobramycin | 1 | 2005 | 9 | 0.070 |
Why?
|
Calcium Sulfate | 1 | 2005 | 19 | 0.070 |
Why?
|
Bone Substitutes | 1 | 2005 | 25 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2011 | 437 | 0.070 |
Why?
|
Feces | 1 | 2005 | 98 | 0.060 |
Why?
|
Humerus | 1 | 2005 | 98 | 0.060 |
Why?
|
Animals | 2 | 2011 | 4552 | 0.060 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2004 | 5 | 0.060 |
Why?
|
Bone Transplantation | 1 | 2005 | 224 | 0.060 |
Why?
|
Practice Guidelines as Topic | 1 | 2005 | 333 | 0.060 |
Why?
|
Administration, Oral | 2 | 2020 | 140 | 0.060 |
Why?
|
Drug Synergism | 2 | 1994 | 63 | 0.050 |
Why?
|
Gram-Negative Bacteria | 2 | 2007 | 37 | 0.050 |
Why?
|
Diagnosis, Differential | 2 | 2006 | 389 | 0.050 |
Why?
|
Ofloxacin | 2 | 1997 | 5 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2005 | 1830 | 0.050 |
Why?
|
Parasitic Diseases | 1 | 1999 | 4 | 0.040 |
Why?
|
Virus Diseases | 1 | 1999 | 17 | 0.040 |
Why?
|
Bacterial Load | 1 | 2018 | 13 | 0.040 |
Why?
|
Gas Gangrene | 1 | 2018 | 1 | 0.040 |
Why?
|
Rectum | 1 | 2018 | 61 | 0.040 |
Why?
|
Leukocidins | 1 | 2018 | 2 | 0.040 |
Why?
|
Dermatomycoses | 1 | 2018 | 3 | 0.040 |
Why?
|
Exotoxins | 1 | 2018 | 14 | 0.040 |
Why?
|
Pyomyositis | 1 | 2018 | 5 | 0.040 |
Why?
|
Substance Abuse, Intravenous | 1 | 2018 | 12 | 0.040 |
Why?
|
Tertiary Care Centers | 1 | 2018 | 65 | 0.040 |
Why?
|
Administration, Intravenous | 1 | 2018 | 29 | 0.040 |
Why?
|
Immunoglobulins | 1 | 2018 | 28 | 0.040 |
Why?
|
Bacterial Toxins | 1 | 2018 | 21 | 0.040 |
Why?
|
Chronic Disease | 1 | 2020 | 495 | 0.040 |
Why?
|
Immunocompromised Host | 1 | 2018 | 45 | 0.040 |
Why?
|
Prodrugs | 1 | 1997 | 4 | 0.040 |
Why?
|
Ceftriaxone | 1 | 1997 | 5 | 0.040 |
Why?
|
Macrolides | 2 | 1994 | 6 | 0.040 |
Why?
|
Cefuroxime | 1 | 1997 | 2 | 0.040 |
Why?
|
Levofloxacin | 1 | 1997 | 5 | 0.040 |
Why?
|
Academic Medical Centers | 1 | 2018 | 142 | 0.040 |
Why?
|
Prevalence | 1 | 2018 | 487 | 0.040 |
Why?
|
Legionnaires' Disease | 1 | 1996 | 1 | 0.040 |
Why?
|
Emergencies | 1 | 1996 | 39 | 0.040 |
Why?
|
Bacteriological Techniques | 1 | 1996 | 20 | 0.040 |
Why?
|
Acute Disease | 1 | 1996 | 226 | 0.030 |
Why?
|
Listeriosis | 1 | 1995 | 5 | 0.030 |
Why?
|
Skin Tests | 1 | 1995 | 14 | 0.030 |
Why?
|
Adolescent | 2 | 2018 | 2279 | 0.030 |
Why?
|
Staphylococcus | 1 | 1995 | 10 | 0.030 |
Why?
|
Drug Utilization | 1 | 1995 | 27 | 0.030 |
Why?
|
Arthritis, Infectious | 1 | 1995 | 59 | 0.030 |
Why?
|
Kinetics | 1 | 1994 | 225 | 0.030 |
Why?
|
Campylobacter coli | 1 | 1993 | 2 | 0.030 |
Why?
|
Metronidazole | 1 | 1993 | 8 | 0.030 |
Why?
|
Borrelia burgdorferi Group | 1 | 1993 | 6 | 0.030 |
Why?
|
Enterocolitis, Pseudomembranous | 1 | 1993 | 16 | 0.030 |
Why?
|
Contraindications | 1 | 2013 | 41 | 0.030 |
Why?
|
Blood | 1 | 2013 | 25 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2013 | 33 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2013 | 223 | 0.030 |
Why?
|
Survival Analysis | 1 | 2013 | 298 | 0.030 |
Why?
|
Serial Passage | 1 | 1992 | 2 | 0.030 |
Why?
|
Topoisomerase II Inhibitors | 1 | 1992 | 2 | 0.030 |
Why?
|
Osteoarthritis, Hip | 1 | 2013 | 94 | 0.030 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 1992 | 9 | 0.030 |
Why?
|
Ureaplasma urealyticum | 1 | 1991 | 1 | 0.030 |
Why?
|
Prospective Studies | 2 | 2013 | 1811 | 0.030 |
Why?
|
Mycoplasma | 1 | 1991 | 4 | 0.030 |
Why?
|
Treponema pallidum | 1 | 1991 | 4 | 0.030 |
Why?
|
Young Adult | 1 | 2018 | 1932 | 0.030 |
Why?
|
Gonorrhea | 1 | 1991 | 8 | 0.030 |
Why?
|
Serratia | 1 | 2010 | 7 | 0.020 |
Why?
|
Syringes | 1 | 2010 | 11 | 0.020 |
Why?
|
Blood Sedimentation | 1 | 2010 | 64 | 0.020 |
Why?
|
Biopsy, Fine-Needle | 1 | 2010 | 50 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2010 | 130 | 0.020 |
Why?
|
Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 7 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2010 | 125 | 0.020 |
Why?
|
Mutation | 1 | 1992 | 383 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2010 | 90 | 0.020 |
Why?
|
Norfloxacin | 1 | 1989 | 2 | 0.020 |
Why?
|
Hip Joint | 1 | 2013 | 367 | 0.020 |
Why?
|
Urinary Tract Infections | 1 | 1989 | 32 | 0.020 |
Why?
|
Osteoarthritis, Knee | 1 | 2013 | 381 | 0.020 |
Why?
|
Pneumonia | 1 | 1989 | 67 | 0.020 |
Why?
|
Knee Joint | 1 | 2013 | 797 | 0.020 |
Why?
|
Coxiella burnetii | 1 | 2006 | 3 | 0.020 |
Why?
|
Antigens, Bacterial | 1 | 2006 | 7 | 0.020 |
Why?
|
Australia | 1 | 2006 | 44 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2011 | 1113 | 0.020 |
Why?
|
Drug Implants | 1 | 2005 | 11 | 0.020 |
Why?
|
Osteomyelitis | 1 | 2005 | 22 | 0.020 |
Why?
|
Dogs | 1 | 2005 | 253 | 0.020 |
Why?
|
Radiography | 1 | 2005 | 678 | 0.010 |
Why?
|
Injections, Intravenous | 1 | 1997 | 56 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 1997 | 241 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 1995 | 125 | 0.010 |
Why?
|
Dysentery, Bacillary | 1 | 1990 | 2 | 0.010 |
Why?
|
Campylobacter fetus | 1 | 1990 | 4 | 0.010 |
Why?
|
Salmonella Infections | 1 | 1990 | 3 | 0.010 |
Why?
|
Double-Blind Method | 1 | 1990 | 503 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 1990 | 340 | 0.010 |
Why?
|